Breaking Finance News

Evoke Pharma Inc (NASDAQ:EVOK) has been upgraded to Sell in a statement by ValuEngine earlier today.

Having a price of $2.59, Evoke Pharma Inc (NASDAQ:EVOK) traded -2.18% lower on the day. With the last close down -17.53% from the two hundred day average, compared with the S&P 500 Index which has increased 0.05% over the same period. Evoke Pharma Inc has recorded a 50-day average of $2.46 and a two hundred day average of $2.72. Trade Volume was up over the average, with 62,045 shares of EVOK changing hands over the typical 55,764

ValuEngine has upgraded Evoke Pharma Inc (NASDAQ:EVOK) to Sell in a statement released on 7/7/2017.

See Chart Below

Evoke Pharma Inc (NASDAQ:EVOK)

Evoke Pharma Inc has a 52 week low of $1.35 and a 52 week high of $4.55 The company’s market cap is currently $0.

In addition to ValuEngine reporting its target price, a total of 7 firms have issued a report on the stock. The consensus target price is $17.68 with 2 firms rating the stock a strong buy, 4 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

General Information About Evoke Pharma Inc (NASDAQ:EVOK)

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.